Tyra Biosciences (TYRA)
(Delayed Data from NSDQ)
$15.67 USD
+0.56 (3.71%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $15.62 -0.05 (-0.32%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TYRA 15.67 +0.56(3.71%)
Will TYRA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TYRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TYRA
Here's What Could Help Tyra Biosciences, Inc. (TYRA) Maintain Its Recent Price Strength
Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 52.22%: Read This Before Placing a Bet
TYRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing'
Wall Street Analysts Believe Tyra Biosciences, Inc. (TYRA) Could Rally 59.17%: Here's is How to Trade
Here's Why 'Trend' Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA)
Other News for TYRA
Tyra Bioscience Poised for Growth: Buy Rating Affirmed Amid Promising Clinical Trials and Strategic Drug Development
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vera Therapeutics (VERA), Tyra Bioscience (TYRA) and Tenaya Therapeutics (TNYA)
Tyra Bioscience Gains Pediatric Disease Designation for Achondroplasia Drug Amid FDA Voucher Uncertainty
Analysts Offer Insights on Healthcare Companies: Nyxoah (NYXH), Tyra Bioscience (TYRA) and Crinetics Pharmaceuticals (CRNX)
Wall Street Analysts Are Bullish on Top Healthcare Picks